Many Young Cancer Patients Not Well Aware of Fertility Preservation Options
July 28th 2015Although it is important for clinicians and their patients who are receiving anticancer treatment to discuss patients' fertility preservation options, a new study has found that whether these conversations take place and, importantly, whether ensuing action is taken, depends on a number of factors.
Women in Appalachia Need Support to Optimize Their Adjuvant Breast Cancer Therapy
July 28th 2015A new study has uncovered notable disparities in uptake of adjuvant breast cancer therapies in the Appalachian region of the United States, suggesting targeted intervention strategies may help to improve outcomes for this population of women.
Expert Group Hopes to Mobilize Patients to Call for Cancer Drug Pricing Reforms
July 23rd 2015A group of 118 well-known cancer experts have come together to spotlight the escalating costs of cancer treatment with an aim to galvanize patients and grassroots advocates to make their voices heard.
Nivolumab Extends Survival in Kidney Cancer
July 22nd 2015A phase III trial evaluating the efficacy of nivolumab (Opdivo) for the treatment of advanced renal cell carcinoma has been stopped early after the immunotherapy agent demonstrated a survival advantage over the comparator drug, everolimus (Afinitor), in the CheckMate-025 trial.
"Hotspots" Highlight Need for Targeted Efforts to Promote Colorectal Cancer Screening
July 8th 2015Researchers have identified three "hotspots" in the United States where progress on reducing death rates from colorectal cancer have lagged, shining a light on areas of the country where efforts to increase screening uptake and promote healthier lifestyles could make a big difference.
The Goodwill of Strangers Helps Build a Unique Resource for Cancer Research
July 3rd 2015Thousands of women have made the selfless choice to literally donate a precious piece of themselves by giving a breast tissue sample to the Susan G. Komen Tissue Bank at the Indiana University Melvin and Bren Simon Cancer Center, a unique resource for researchers worldwide.
Single-Dose Fosaprepitant Effective in Preventing CINV with Moderately Emetogenic Chemotherapy
July 1st 2015A single intravenous dose of fosaprepitant dimeglumine was shown to be superior to placebo when either were combined with other anti-vomiting agents for protection against chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy.